Vermillion (NASDAQ:VRML) is scheduled to announce its earnings results after the market closes on Tuesday, May 14th.
Vermillion (NASDAQ:VRML) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The firm had revenue of $0.92 million for the quarter. Vermillion had a negative net margin of 372.45% and a negative return on equity of 150.85%.
Shares of NASDAQ:VRML opened at $1.33 on Monday. Vermillion has a fifty-two week low of $0.27 and a fifty-two week high of $1.57. The company has a current ratio of 3.64, a quick ratio of 3.61 and a debt-to-equity ratio of 0.18.
In related news, Director David Schreiber sold 30,000 shares of Vermillion stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $1.00, for a total value of $30,000.00. Following the sale, the director now directly owns 137,405 shares in the company, valued at approximately $137,405. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 4.25% of the company’s stock.
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Recommended Story: How is net asset value different from market price?
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.